{"filing":{"accession_number":"0001140361-26-025440","cik":"0001228627","ticker":"IRD","company_name":"Opus Genetics, Inc.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"ef20076319_form8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036126025440/ef20076319_form8k.htm"},"events":[{"id":11309,"run_id":9927,"accession_number":"0001140361-26-025440","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"The filing discloses a press release highlighting five gene therapy programs targeting inherited retinal diseases. This is a material corporate development disclosure that does not fit neatly into the standard taxonomy categories—it is neither an earnings release, M\u0026A activity, executive change, nor litigation. For a biotech company, disclosure of multiple gene therapy programs represents material pipeline information that would affect investor assessment of the company's prospects and competitive position.","company_name":"Opus Genetics, Inc.","ticker":"IRD","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7867,"accession_number":"0001140361-26-025440","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses a press release highlighting five gene therapy programs targeting inherited retinal diseases. This is a material corporate development disclosure that does not fit neatly into the standard taxonomy categories—it is neither an earnings release, M\u0026A activity, executive change, nor litigation. For a biotech company, disclosure of multiple gene therapy programs represents material pipeline information that would affect investor assessment of the company's prospects and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:12:06.390521+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7867,"accession_number":"0001140361-26-025440","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses a press release highlighting five gene therapy programs targeting inherited retinal diseases. This is a material corporate development disclosure that does not fit neatly into the standard taxonomy categories—it is neither an earnings release, M\u0026A activity, executive change, nor litigation. For a biotech company, disclosure of multiple gene therapy programs represents material pipeline information that would affect investor assessment of the company's prospects and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:12:06.390521+00:00","company_name":"Opus Genetics, Inc.","ticker":"IRD","filing_date":"2026-06-16"}]}